Easton Pharmaceuticals Inc (PK:EAPH)
Business Focus: Bio Therapeutic Drugs
You may also be interested in
Insider Filings
Latest 10 SEC Form 4 filings for EAPH*US within the last 6 months
See all filings within the past 6 months
Read full article
Read full article
See more news stories
See all valuations
Loading...
Company News
Jun 13, 2019 08:30 ET
Easton Pharmaceuticals Turns to Profit in Q1, Provides Business Update
via NetworkWire -- Easton Pharmaceuticals Inc. (OTC: EAPH) (“Easton” or “the Company”) announces it has filed its quarterly report for the three months ended March 31, 2019, and provides several key updates on its business initiatives. Q1 Filing...
Apr 30, 2019 15:20 ET
Easton Announces That it Is Moving its Corporate Office After the Purchase of its Food Processing Company Specializing in Baked Goods and the Launch of its New Website
TORONTO, ON / ACCESSWIRE / April 30, 2019 / Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) executive management is pleased to announce the move of its corporate head office from Elm Street, Toronto, Ontario to Brockhouse Road, Toronto, Ontario.
Valuation Ratios
Industry
Sector
Beta
-5.57
--
--
Price to Sales - TTM
--
5.94
3.14
Price to Book - most recent quarter
0.00
2.19
2.08
Price to Cash Flow per share - TTM
--
17.66
13.73
Price to Free Cash Flow per share - TTM
--
16.96
23.65
Business Summary
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
Easton Pharmaceuticals, Inc. is a development-stage company engaged in various pharmaceutical sectors and others industries. The Company has a transdermal delivery technology (Viorra Delivery Matrix or VDM), which is incorporated in a line of therapeutic over-the-counter (OTC) products. The Company owns topically-delivered drugs and therapeutic/cosmetic healthcare products focused on cancer and other health problems geared towards female sexual dysfunction, wound healing, pain, motion sickness and other conditions. The Company's products are in various stages of commercialization. The Company's products include Nauseasol, which is a motion sickness gel; Skin Renou HA, which is an anti-aging wrinkle cream; Kenestrin Gel, which is a is a pain relief gel; Viorra, which serves as an aid to the relief of female sexual arousal disorder (FSAD); XILIVE, which is an early-stage cancer drug, and FSAD) drug, which includes a water-based complex polymer matrix.
See business summary
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
